Protection from viremia and disease progression in SIVBK28 infected Macaca mulatta, challenged with SIVmac251/32H

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Protection from viremia and disease progression in SIVBK28 infected Macaca mulatta, challenged with SIVmac251/32H

Int Conf AIDS. 1991 Jun 16-21;7(1):158 (abstract no. M.A.1264). Unique Identifier : AIDSLINE ICA7/1126491
Niphuis H; Heeney JL; ITRI-TNO, Dept. of Chronic and Infectious Diseases, Rijswijk, The; Netherlands

Abstract: Various strains of the HIV-2 related SIVsm group of primate lentiviruses have different pathogenic properties in Macaca mulatta. SIVBK28 is a relatively non-pathogenic and non-viremic strain causing persistent infection with a strong persistent immune response. OBJECTIVE: To determine if prior infection with a minimally virulent strain influences disease progression after subsequent challenge with a virulent strain. METHODS: Rhesus monkeys infected with SIVBK28 for over 2 years and challenged with 100 MID of the 8811 stock of SIVmac251/32H. RESULTS: Prior infection with SIVBK28 protected three out of four animals from viremia as detected by antigen capture and four out of four from disease progression as determined by absolute CD4/CD29 counts. The two controls infected with 100 MID of SIVmac251/32H developed viremia and developed terminal disease while unchallenged SIVBK28 infected monkeys remain disease free. These data supports observations that viremia is an important factor in disease progression and secondly demonstrates that prior infection with minimally pathogenic strains may permit acquisition of sufficient protective immunity to limit subsequent infection(s) by more virulent strains. CONCLUSIONS: These findings suggest that the pathogenic or virulence properties of the initial inoculum may influence establishment of subsequent HIV strains and greatly influence the course of disease.

Keywords: Animal Antigens, CD/ANALYSIS Antigens, CD4/ANALYSIS Macaca mulatta Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/ MICROBIOLOGY SIV/*IMMUNOLOGY Virulence ABSTRACT
912130
M91C3691

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .